Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ProTip Medical Closes USD 4.7 (EUR 3.8) Million Financing Round

Published: Tuesday, November 27, 2012
Last Updated: Tuesday, November 27, 2012
Bookmark and Share
Funds will advance clinical development of ProTip’s ENTegral™, world’s first permanent implant to replace the larynx in patients who have undergone a total laryngectomy.

ProTip SA has announced a USD 4.7 (EUR 3.8) million Series C financing round. The round was led by new VC investor Seventure, along with existing investors including Fonds Lorrain des Materiaux (FLM), the Berchet family-office, Alsace Amorcage and other private investors.

ProTip will use the funding to complete the company’s first human clinical trial of its ENTegral™ device, the world’s first permanent implant to replace the larynx in patients who have undergone a total laryngectomy.

It will also launch wider trials with the aim of bringing the implant to market. Since inception, ProTip has raised a total of EUR 6.8 million and has managed its development closely in line with its business plan.

"We are extremely pleased to welcome Seventure as a new partner,” said Maurice Berenger, CEO of ProTip. “More than mere financial resources, Seventure brings us its expertise and a conclusive track record as an experienced medical device investor.”

“There is currently no available solution for laryngectomized patients. ProTip’s ENTegral™ is designed to allow patients to go back to a normal, unimpaired social life,” added Berenger. “This Series C cash infusion will enable ProTip to move forward with this breakthrough medical device."

“We have been particularly attracted by the quality of the product portfolio dedicated to ear, nose and throat (ENT) applications, a medical sector where very few major innovations have come out these last few years,” said Emmanuel Fiessinger, general partner at Seventure.

Fiessinger continued, “The team has very high level financial and academic partners committed to this project, including a very strong public-private alliance, and this definitively convinced Seventure to support this company.”

“To have Seventure on board in this exciting venture is a further endorsement of the quality of the company,” said Laurent Bocahut, investment manager at FLM and member of ProTip’s supervisory board.

Bocahut continued, “With this successful round, ProTip is in an excellent position to become a market leader in the field of laryngology. This great achievement illustrates the quality and proficiency of ProTip’s operational team.”

“Today, there is no available treatment that alleviates the need for a definitive tracheotomy for patients having undergone total laryngectomy,” said Christian Debry, MD, PhD, head of ENT department at Strasbourg Teaching Hospital and co-founder of ProTip.

Debry continued, “The ENTegral implant aims to restore respiration through natural ways and to give laryngectomized patients access to a much better life.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
First Made-in-Singapore Cancer Drug Enters Clinical Testing
The drug prevents cancer progression and paves the way for new advancements in cancer therapeutics.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!